Cargando…

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS

Detalles Bibliográficos
Autores principales:	Bruins, Wassilis, Duetz, Carolien, Groen, Kaz, Korst, Charlotte, de Jonge, Vera, Verkleij, Christie, Rentenaar, Rosa, Cosovic, Meliha, van de Donk, Niels W.C.J., Zweegman, Sonja, Mutis, Tuna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428238/ http://dx.doi.org/10.1097/01.HS9.0000967660.28577.c3

Ejemplares similares

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
por: Frerichs, Kristine, et al.
Publicado: (2023)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

S187. EXPLORING NEURODEVELOPMENTAL AND FAMILIAL ORIGINS OF NEUROLOGICAL SOFT SIGNS IN SCHIZOPHRENIA
por: Cooper, Rebecca, et al.
Publicado: (2020)

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
por: Brink, Mirian, et al.
Publicado: (2021)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
por: Seefat, Maarten R., et al.
Publicado: (2021)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

M187. A MULTIMODAL, NEUROIMAGING STUDY OF TDCS MECHANISMS RELATED TO AUDITORY VERBAL HALLUCINATIONS IN HEALTHY INDIVIDUALS
por: Lynn, Marquardt, et al.
Publicado: (2020)

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)

The decay of $^{187}$Pt: comparison of the levels of $^{187}$Ir
por: Sébille-Schück, C, et al.
Publicado: (1973)

P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
por: de Jonge, V., et al.
Publicado: (2022)

Memorandum 187
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1984)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Measurements of the $(n,\gamma)$ and (n,n') reaction cross sections on $^{186,187,189}Os$ and $^{187}Re-^{187}Os$ cosmochronology
por: Segawa, M, et al.
Publicado: (2006)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms
por: Duetz, Carolien, et al.
Publicado: (2023)

187 Aniversario. Los tratados de Córdoba
Publicado: (2008)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

TOB transport building 187
por: Sylvie Prodon
Publicado: (2003)

S188: CAR-T CELLS SHAPE THE IMMUNOLOGICAL POTENTIAL OF THE TUMOR MICROENVIRONMENT
por: Frede, Julia, et al.
Publicado: (2023)

T187. ATHENS MULTIFAMILY THERAPY PROJECT THE ATHENS MULTIFAMILY THERAPY PROJECT (A- MFTP) PROVIDES SYSTEMIC MULTIFAMILY GROUP THERAPY TO YOUTHS WHO EXPERIENCED A FIRST PSYCHOTIC EPISODE (FEP) AND THEIR FAMILIES
por: Selakovic, Mirjana, et al.
Publicado: (2020)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

The Childbirth Experience Survey (CBEX) and COVID-19: the ABCs of vaccine hesitancy in postpartum people
por: Saeb, Samia, et al.
Publicado: (2022)

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Smits, F., et al.
Publicado: (2023)

Study of the radioactive disintegration of /sup 187/Au: existence of E0 transitions in /sup 187/Pt?
por: Braham, A B, et al.
Publicado: (1979)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iq1nc6k5kgo6tbu695jn1mctan